• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲磺酸伊马替尼治疗不可切除或复发性胃肠道间质瘤患者：来自越南的 10 年经验。

Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam.

机构信息

1 Department of Medical Oncology, Vietnam National Cancer Hospital-K Hospital, Hanoi, Vietnam.

2 Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.

出版信息

Cancer Control. 2019 Jan-Dec;26(1):1073274819863776. doi: 10.1177/1073274819863776.

DOI:10.1177/1073274819863776
PMID:31319677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6643187/
Abstract

Only limited data are available concerning the long-term outcomes of imatinib treatment among Vietnamese or Asian patients with unresectable or recurrent gastrointestinal stromal tumors (GISTs). Our study, which was conducted in 188 patients, aimed to assess the efficacy of imatinib mesylate against unresectable or recurrent GISTs. Imatinib had a high response rate and long survival. Some predictors favorable for progression-free survival and overall survival are good performance status and response with imatinib. Findings are discussed in relation to clinical practice in low- and middle-income country.

摘要

关于不可切除或复发性胃肠道间质瘤（GIST）患者的伊马替尼治疗的长期结果，仅有有限的数据。我们的研究纳入了 188 例患者，旨在评估甲磺酸伊马替尼治疗不可切除或复发性 GIST 的疗效。伊马替尼具有较高的缓解率和较长的生存时间。对无进展生存和总生存有预测价值的因素包括良好的体能状态和伊马替尼的反应。研究结果与中低收入国家的临床实践相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/610f/6643187/a1277511519a/10.1177_1073274819863776-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/610f/6643187/41e549483e97/10.1177_1073274819863776-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/610f/6643187/a1277511519a/10.1177_1073274819863776-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/610f/6643187/41e549483e97/10.1177_1073274819863776-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/610f/6643187/a1277511519a/10.1177_1073274819863776-fig2.jpg

相似文献

1
Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam.甲磺酸伊马替尼治疗不可切除或复发性胃肠道间质瘤患者：来自越南的 10 年经验。
Cancer Control. 2019 Jan-Dec;26(1):1073274819863776. doi: 10.1177/1073274819863776.
2
Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.不可切除或复发性胃肠道间质瘤患者的长期伊马替尼治疗。
Digestion. 2018;97(1):20-25. doi: 10.1159/000484102. Epub 2018 Feb 1.
3
Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.甲磺酸伊马替尼治疗复发性和不可切除胃肠道间质瘤的长期随访结果。
Digestion. 2013;87(1):47-52. doi: 10.1159/000343938. Epub 2013 Jan 21.
4
Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.胃肠道间质瘤转移或复发患者采用酪氨酸激酶抑制剂和手术干预的长期生存结局：14 年单中心经验。
Cancer Med. 2019 Mar;8(3):1034-1043. doi: 10.1002/cam4.1994. Epub 2019 Jan 28.
5
Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.局部晚期和复发性/转移性胃肠道间质瘤的术前辅助治疗：一项回顾性研究。
World J Surg Oncol. 2020 Apr 7;18(1):70. doi: 10.1186/s12957-020-01840-9.
6
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.达沙替尼治疗对伊马替尼耐药的晚期胃肠间质瘤患者的无进展生存期的影响。
JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.
7
Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.直肠胃肠道间质瘤（GIST）在伊马替尼时代：器官保存和改善的肿瘤学结果。
Ann Surg Oncol. 2017 Dec;24(13):3972-3980. doi: 10.1245/s10434-017-6087-9. Epub 2017 Oct 20.
8
Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.伊马替尼继发耐药后的预后因素：不可切除和转移性胃肠道间质瘤患者的生存分析
Int J Clin Oncol. 2016 Apr;21(2):295-301. doi: 10.1007/s10147-015-0903-7. Epub 2015 Sep 19.
9
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).手术在对伊马替尼敏感的复发性、转移性或不可切除的局部晚期胃肠道间质瘤患者中的作用：西班牙肉瘤研究小组（GEIS）的回顾性分析
Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8. Epub 2015 Jan 22.
10
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.经一线伊马替尼治疗获益延长的转移性胃肠间质瘤的临床病理和分子特征。
Oncologist. 2019 May;24(5):680-687. doi: 10.1634/theoncologist.2018-0032. Epub 2018 Aug 20.

引用本文的文献

1
Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature.接受酪氨酸激酶抑制剂治疗的胃肠道间质瘤（GIST）患者的健康相关生活质量和副作用：文献系统评价
Cancers (Basel). 2022 Apr 5;14(7):1832. doi: 10.3390/cancers14071832.
2
A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth.一种新型单克隆抗体，可阻断二聚化并抑制 c-kit 突变驱动的肿瘤生长。
J Cancer Res Clin Oncol. 2021 Apr;147(4):1065-1075. doi: 10.1007/s00432-020-03490-6. Epub 2021 Jan 3.
3
BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST.

本文引用的文献

1
Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.不可切除或复发性胃肠道间质瘤患者的长期伊马替尼治疗。
Digestion. 2018;97(1):20-25. doi: 10.1159/000484102. Epub 2018 Feb 1.
2
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.无法切除或转移性胃肠道间质瘤患者的 10 年无进展生存和总生存：欧洲癌症研究与治疗组织、意大利肉瘤研究组和澳大拉西亚胃肠肿瘤试验组间组 3 期随机试验中伊马替尼两种剂量水平的长期分析。
J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.
3
BRD4 促进 GIST 中的肿瘤进展和 NF-κB/CCL2 依赖性肿瘤相关巨噬细胞募集。
Cell Death Dis. 2019 Dec 9;10(12):935. doi: 10.1038/s41419-019-2170-4.
4
Scientific Evidence for Cancer Control in Vietnam.越南癌症防控的科学证据。
Cancer Control. 2019 Jan-Dec;26(1):1073274819866450. doi: 10.1177/1073274819866450.
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.胃肠道间质瘤（GIST）的全球流行病学：基于人群队列研究的系统评价
Cancer Epidemiol. 2016 Feb;40:39-46. doi: 10.1016/j.canep.2015.10.031. Epub 2015 Nov 24.
4
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.伊马替尼治疗转移性胃肠道间质瘤的预后列线图的开发与验证
Eur J Cancer. 2015 May;51(7):852-60. doi: 10.1016/j.ejca.2015.02.015. Epub 2015 Mar 19.
5
A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.多中心长期研究伊马替尼治疗不可切除或复发性胃肠道间质瘤的日本患者。
J Surg Oncol. 2014 Dec;110(8):942-6. doi: 10.1002/jso.23773. Epub 2014 Aug 28.
6
Incidence and survival analysis of gastrointestinal stromal tumors in shanghai: a population-based study from 2001 to 2010.上海地区胃肠间质瘤的发病率与生存分析：一项基于人群的 2001 至 2010 年研究。
Gastroenterol Res Pract. 2014;2014:834136. doi: 10.1155/2014/834136. Epub 2014 Apr 23.
7
Long-term efficacy of imatinib for treatment of metastatic GIST.伊马替尼治疗转移性 GIST 的长期疗效。
Cancer Chemother Pharmacol. 2013 Aug;72(2):277-86. doi: 10.1007/s00280-013-2135-8. Epub 2013 Mar 17.
8
A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia.捷克共和国和斯洛伐克胃肠道间质瘤的全人群研究。
Neoplasma. 2009;56(5):459-64. doi: 10.4149/neo_2009_05_459.
9
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.伊马替尼的血浆水平与不可切除/转移性胃肠道间质瘤患者的临床获益相关。
J Clin Oncol. 2009 Jul 1;27(19):3141-7. doi: 10.1200/JCO.2008.20.4818. Epub 2009 May 18.
10
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.一项关于甲磺酸伊马替尼用于韩国转移性或不可切除胃肠道间质瘤患者的前瞻性、多中心、2期研究。
Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.